Background
Previous studies on magnetic resonance neurography (MRN) found different patterns of structural nerve damage in type 1 diabetes (T1D) and type 2 diabetes (T2D). Magnetization transfer ratio (MTR) is a quantitative technique to analyze the macromolecular tissue composition. We compared MTR values of the sciatic nerve in patients with T1D, T2D, and healthy controls (HC).
Methods
3-T MRN of the right sciatic nerve at thigh level was performed in 14 HC, 10 patients with T1D (3 with diabetic neuropathy), and 28 patients with T2D (10 with diabetic neuropathy). Results were subsequently correlated with clinical and electrophysiological data.
Results
The sciatic nerve’s MTR was lower in patients with T2D (0.211 ± 0.07, mean ± standard deviation) compared to patients with T1D (T1D 0.285 ± 0.03;
p
 = 0.015) and HC (0.269 ± 0.05;
p
 = 0.039). In patients with T1D, sciatic MTR correlated positively with tibial nerve conduction velocity (NCV;
r
 = 0.71;
p
 = 0.021) and negatively with hemoglobin A1c (
r
 =  − 0.63;
p
 < 0.050). In patients with T2D, we found negative correlations of sciatic nerve’s MTR peroneal NCV (
r
 =  − 0.44;
p
 = 0.031) which remained significant after partial correlation analysis controlled for age and body mass index (
r
 = 0.51;
p
 = 0.016).
Conclusions
Lower MTR values of the sciatic nerve in T2D compared to T1D and HC and diametrical correlations of MTR values with NCV in T1D and T2D indicate that there are different macromolecular changes and pathophysiological pathways underlying the development of neuropathic nerve damage in T1D and T2D.
Trial registration
https://classic.clinicaltrials.gov/ct2/show/NCT03022721
. 16 January 2017.
Relevance statement
Magnetization transfer ratio imaging may serve as a non-invasive imaging method to monitor the diseases progress and to encode the pathophysiology of nerve damage in patients with type 1 and type 2 diabetes.
Key points
• Magnetization transfer imaging detects distinct macromolecular nerve l...

Magnetization transfer ratio of the sciatic nerve differs between patients in type 1 and type 2 diabetes

10.1186/s41747-023-00405-1